Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Firms Share NDI Notification Tips And Experts Reveal Common Pitfalls

This article was originally published in The Tan Sheet

Executive Summary

Early and frequent communication with FDA is key to earning an elusive FDA acceptance of a new dietary ingredient notification on the first try, an agriculture-tech firm executive says

You may also be interested in...



Artful Approach Improves NDI Notifications’ Chances At FDA

FDA accepts only 25% of NDI notifications on first submission, but firms can improve their chances by organizing notifications in easy-to-read narratives, suggests attorney Ashish Talati. Hiring independent toxicologists to review safety also can boost a firm’s chance at success.

Artful Approach Improves NDI Notifications’ Chances At FDA

FDA accepts only 25% of NDI notifications on first submission, but firms can improve their chances by organizing notifications in easy-to-read narratives, suggests attorney Ashish Talati. Hiring independent toxicologists to review safety also can boost a firm’s chance at success.

GRAS Path Draws Interest As New Dietary Ingredient Alternative, But Carries Challenges

In the wake of FDA’s draft guidance on NDI notifications, more companies reevaluate the status of their ingredients before going to market. The GRAS for use in foods process is a clear – but rigorous – alternative pathway.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS103704

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel